SCHEMBL6792289

SCHEMBL6792289

C/C(=C/C(=O)Nc1ccc(F)cc1C(=O)O)c1cccnc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.48
DHODH Q02127 4/20 0.43
ALDH1A1 P00352 3/20 0.43
CYP11B1 P15538 1/20 0.43
RAB9A P51151 2/20 0.42
AGTR1 P30556 1/20 0.42
OPRK1 P41145 1/20 0.42
GAA P10253 3/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
THRB P10828 1/20 0.41
HPGD P15428 1/20 0.41
HDAC1 Q13547 1/20 0.41
ABCB1 P08183 2/20 0.41
DEGS1 O15121 1/20 0.41
APP P05067 1/20 0.40
HCAR3 P49019 1/20 0.40
HCAR2 Q8TDS4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6787380 0.81 MEN1 (0.52) TERTDHODHMAPTDEGS1
SCHEMBL6790635 0.79 TERT (0.52) TERTDHODHDEGS1
SCHEMBL6787516 0.79 TERT (0.55) TERTDHODHALDH1A1RAB9AGAA
SCHEMBL4020296 0.79 TERT (0.77) TERTDHODHKDM4EDEGS1
SCHEMBL6785899 0.78 TERT (0.54) TERTDHODHALDH1A1RAB9AKDM4E
SCHEMBL6785956 0.77 TERT (0.53) TERTDHODHKDM4E
SCHEMBL6788013 0.76 TERT (0.62) TERTDHODHALDH1A1MAPT
SCHEMBL6781608 0.76 CYP3A4 (0.53) TERTALDH1A1RAB9AGAAKDM4E
SCHEMBL6783990 0.75 TERT (0.47) TERTDHODHHPGDDEGS1
SCHEMBL6782589 0.74 DHODH (0.58) TERTDHODHALDH1A1RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885DHODH 1011/4885ALDH1A1 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.